Literature DB >> 23925678

Quetiapine may reduce hospital admission rates in patients with mental health problems and alcohol addiction.

C Kong1, W Chiu, A Davies, J Keating.   

Abstract

A 64-year-old man presented with 40 years history of chronic alcohol excess. On average, he had six hospital admissions a year with alcohol-related problems for at least a 10-year period. In 2009, he considered reducing his alcohol intake. He was noted to have mood disturbances, was seen by a psychogeriatrician who diagnosed bipolar disorder. He tried various bipolar medications including lithium and sodium valproate which was unsuccessful. He was then started on quetiapine 600 mg a day in divided doses. Subsequently this has not only controlled the bipolar disorder but also resulted in significant reduction in alcohol intake. He now shares a bottle of wine with his wife while in the past he was consuming a bottle of scotch daily. This case illustrates the benefits of quetiapine in assisting with this man's addiction to alcohol.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23925678      PMCID: PMC3762153          DOI: 10.1136/bcr-2013-009817

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  4 in total

1.  Quetiapine improves response inhibition in alcohol dependent patients: a placebo-controlled pilot study.

Authors:  Nathasha Moallem; Lara A Ray
Journal:  Pharmacol Biochem Behav       Date:  2011-10-20       Impact factor: 3.533

2.  Potential benefits of quetiapine in the treatment of substance dependence disorders.

Authors:  S Pirzada Sattar; Subhash C Bhatia; Frederick Petty
Journal:  J Psychiatry Neurosci       Date:  2004-11       Impact factor: 6.186

3.  Quetiapine for treatment of alcohol dependence.

Authors:  Edward P Monnelly; Domenic A Ciraulo; Clifford Knapp; Joseph LoCastro; Isaias Sepulveda
Journal:  J Clin Psychopharmacol       Date:  2004-10       Impact factor: 3.153

4.  Do atypical antipsychotics effectively treat co-occurring bipolar disorder and stimulant dependence? A randomized, double-blind trial.

Authors:  Vicki A Nejtek; Matthew Avila; Li-Ann Chen; Tanya Zielinski; Marija Djokovic; Alan Podawiltz; Kathryn Kaiser; Sejong Bae; A John Rush
Journal:  J Clin Psychiatry       Date:  2008-08       Impact factor: 4.384

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.